The Potential of Computational Modeling to Predict Disease Course and Treatment Response in Patients with Relapsing Multiple Sclerosis

As of today, 20 disease-modifying drugs (DMDs) have been approved for the treatment of relapsing multiple sclerosis (MS) and, based on their efficacy, they can be grouped into moderate-efficacy DMDs and high-efficacy DMDs. The choice of the drug mostly relies on the judgment and experience of neurol...

Descripción completa

Detalles Bibliográficos
Autores principales: Pappalardo, Francesco, Russo, Giulia, Pennisi, Marzio, Parasiliti Palumbo, Giuseppe Alessandro, Sgroi, Giuseppe, Motta, Santo, Maimone, Davide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140535/
https://www.ncbi.nlm.nih.gov/pubmed/32121606
http://dx.doi.org/10.3390/cells9030586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140535/
https://www.ncbi.nlm.nih.gov/pubmed/32121606
http://dx.doi.org/10.3390/cells9030586

Ejemplares similares